Nucleotide Binding Oligomerization Domain 2 Deficiency Leads to Dysregulated TLR2 Signaling and Induction of Antigen-specific Colitis
Overview
Affiliations
In this study, we determined conditions leading to the development of colitis in mice with nucleotide binding oligomerization domain 2 (NOD2) deficiency, a susceptibility factor in Crohn's disease. We found that NOD2-deficient antigen-presenting cells (APCs) produced increased amounts of interleukin (IL)-12 in the presence of ovalbumin (OVA) peptide and peptidoglycan or recombinant E. coli that express OVA peptide (ECOVA). Furthermore, these APCs elicited heightened interferon-gamma (IFN-gamma) responses from cocultured OVA-specific CD4+ T cells. We then demonstrated that NOD2-deficient mice adoptively transferred OVA-specific CD4+ T cells and that administered intrarectal ECOVA developed colitis associated with the expansion of OVA-specific CD4+ T cells producing IFN-gamma. Importantly, this colitis was highly dependent on Toll-like receptor 2 (TLR2) function since it was suppressed in NOD2 and TLR2 double-deficient mice. Thus, NOD2-deficient mice become susceptible to colitis as a result of increased TLR2 responses when they have the capacity to respond to an antigen expressed by mucosal bacteria.
Masaki S, Masuta Y, Honjo H, Kudo M, Watanabe T Front Immunol. 2024; 15:1433620.
PMID: 39403381 PMC: 11471532. DOI: 10.3389/fimmu.2024.1433620.
Innate immunity gene Nod2 protects mice from orthotopic breast cancer.
Gurses S, Varghese N, Gupta D Mol Biol Rep. 2024; 51(1):988.
PMID: 39285089 PMC: 11405536. DOI: 10.1007/s11033-024-09927-2.
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis.
Okai N, Masuta Y, Otsuka Y, Hara A, Masaki S, Kamata K J Clin Biochem Nutr. 2024; 74(2):146-153.
PMID: 38510686 PMC: 10948350. DOI: 10.3164/jcbn.23-87.
The role of gut microbiota in intestinal disease: from an oxidative stress perspective.
Sun Y, Wang X, Li L, Zhong C, Zhang Y, Yang X Front Microbiol. 2024; 15:1328324.
PMID: 38419631 PMC: 10899708. DOI: 10.3389/fmicb.2024.1328324.
Zhuo Z, Guo K, Luo Y, Yang Q, Wu H, Zeng R Theranostics. 2024; 14(2):528-546.
PMID: 38169633 PMC: 10758062. DOI: 10.7150/thno.87739.